(Q45227205)

English

Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: Lessons learned from a gynecologic oncology group phase II trial of ip cisplatin and recombinant α-interferon

scientific article published on April 1, 1992

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: Lessons learned from a gynecologic oncology group phase II trial of ip cisplatin and recombinant α-interferon (English)

reason for preferred rank

most precise value

1 reference

10.1016/0090-8258(92)90482-X

https://api.crossref.org/works/10.1016/0090-8258(92)90482-X

13 October 2022

Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1601332

13 October 2022

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

lessons learned

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

10.1016/0090-8258(92)90482-X

https://api.crossref.org/works/10.1016/0090-8258(92)90482-X

13 October 2022

author name string

McGuire WP

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

M. Markman

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1601332

13 October 2022

J. S. Berek

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1601332

13 October 2022

J. A. Blessing

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1601332

13 October 2022

W. P. McGuire

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1601332

13 October 2022

J. Bell

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1601332

13 October 2022

H. D. Homesley

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1601332

13 October 2022

language of work or name

0 references

publication date

1 April 1992

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

full work available at URL

https://api.elsevier.com/content/article/PII:009082589290482X?httpAccept=text/xml

1 reference

10.1016/0090-8258(92)90482-X

https://api.crossref.org/works/10.1016/0090-8258(92)90482-X

13 October 2022

https://api.elsevier.com/content/article/PII:009082589290482X?httpAccept=text/plain

1 reference

10.1016/0090-8258(92)90482-X

https://api.crossref.org/works/10.1016/0090-8258(92)90482-X

13 October 2022

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

3-8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Intraperitoneal therapy in the management of ovarian carcinoma

1

1 reference

10.1016/0090-8258(92)90482-X

https://api.crossref.org/works/10.1016/0090-8258(92)90482-X

13 October 2022

High-Dose Cisplatin in Hypertonic Saline

3

1 reference

10.1016/0090-8258(92)90482-X

https://api.crossref.org/works/10.1016/0090-8258(92)90482-X

13 October 2022

Dose intensity analysis of chemotherapy regimens in ovarian carcinoma

5

1 reference

10.1016/0090-8258(92)90482-X

https://api.crossref.org/works/10.1016/0090-8258(92)90482-X

13 October 2022

Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer

7

1 reference

10.1016/0090-8258(92)90482-X

https://api.crossref.org/works/10.1016/0090-8258(92)90482-X

13 October 2022

A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer

8

1 reference

10.1016/0090-8258(92)90482-X

https://api.crossref.org/works/10.1016/0090-8258(92)90482-X

13 October 2022

Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer

13

1 reference

10.1016/0090-8258(92)90482-X

https://api.crossref.org/works/10.1016/0090-8258(92)90482-X

13 October 2022

Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study

16

1 reference

10.1016/0090-8258(92)90482-X

https://api.crossref.org/works/10.1016/0090-8258(92)90482-X

13 October 2022

Identifiers

10.1016/0090-8258(92)90482-X

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45227205&oldid=1749969088"